Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Howard Pratt

Psychiatry Miami, FL Doctor of Osteopathy

NPI 1033526785 CMS profile 734797

10300 S.W. 216Th Street, Miami, FL 33190

Open in the dashboard

General payments

$13,414

234 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Howard Pratt of Miami, FL is reported in the CMS Open Payments database as having received $13,414 across 234 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,520 76
2024 General $1,425 43
2023 General $525 14
2022 General $322 15
2021 General $678 34
2020 General $510 29
2019 General $434 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Howard Pratt
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Howard Pratt were reported at $9,520. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Howard Pratt Psychiatry median Middle half National median
2019 $434 $184 $59–$605 $163
2020 $510 $119 $36–$372 $114
2021 $678 $143 $43–$576 $132
2022 $322 $153 $50–$590 $149
2023 $525 $170 $56–$651 $160
2024 $1,425 $179 $57–$673 $164
2025 $9,520 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $7,109 21 payments
  2. Neurocrine Biosciences, Inc. $2,145 49 payments
  3. Teva Pharmaceuticals USA, Inc. $1,601 33 payments
  4. AbbVie, Inc. $601 39 payments
  5. Janssen Pharmaceuticals, Inc $496 25 payments
  6. Alkermes, Inc. $369 17 payments
  7. Indivior Inc. $267 12 payments
  8. Otsuka America Pharmaceutical, Inc. $215 11 payments
  9. Allergan Inc. $170 11 payments
  10. Sunovion Pharmaceuticals Inc. $139 7 payments
  11. Other $303 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,025 230 payments
  2. Consulting Fee $5,520 1 payment
  3. Travel and Lodging $797 2 payments
  4. Education $71 1 payment
Products named General payments · program years 2019–2025
  1. INGREZZA $1,811 34 payments
  2. Austedo XR $788 14 payments
  3. VRAYLAR $523 35 payments
  4. INVEGA SUSTENNA $513 24 payments
  5. COBENFY $487 13 payments
  6. UZEDY $406 5 payments
  7. AUSTEDO $336 13 payments
  8. ARISTADA Cns $321 15 payments
  9. ARISTADA Cns $321 15 payments
  10. ARISTADA Cns $297 14 payments
  11. Other $2,490 117 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

700

Median for Psychiatry: 574

Drug cost

$8,681

Median for Psychiatry: $27,624

Branded share of claims

8.4%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Quetiapine Fumarate Generic 71 $1,118
Quetiapine Fumarate Er Quetiapine Fumarate Brand 14 $850
Haloperidol Decanoate Generic 16 $761
Fluvoxamine Maleate Generic 14 $709
Aripiprazole Generic 15 $637
Divalproex Sodium Generic 25 $509
Olanzapine Generic 31 $499
Benztropine Mesylate Generic 48 $411
Risperidone Generic 45 $393
Haloperidol Generic 20 $385

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $609
$609 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $245
$245 — —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $205
$205 — —
VRAYLAR
  • AbbVie, Inc. $190
$190 — —
PERSERIS
  • Indivior Inc. $75
$75 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

234 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record